1. Clodronate detection and effects on markers of bone resorption are prolonged following a single administration to horses.
- Author
-
Knych HK, Finno CJ, Katzman S, Ryan D, McKemie DS, Kass PH, and Arthur RM
- Subjects
- Horses, Animals, Clodronic Acid pharmacology, Clodronic Acid therapeutic use, Diphosphonates therapeutic use, Biomarkers, Bone Resorption drug therapy, Bone Resorption veterinary, Body Fluids, Horse Diseases drug therapy
- Abstract
Background: Clodronate is a potent antiresorptive agent labelled for use in horses over 4 years of age, for the treatment of navicular syndrome. Concerns regarding the extra-label use of clodronate in equine athletes, such as racehorses, have been raised as inhibition of osteoclast activity by clodronate has been postulated to interfere with normal bone healing, which is imperative to the repair of microfractures. The paucity of data describing the long-term pharmacokinetics of clodronate and effects on biomarkers of bone resorption necessitates further study., Objectives: (1) To determine clodronate concentrations in blood and urine over a 6-month period in horses undergoing treadmill exercise and (2) to assess the effects of clodronate on protein biomarkers of bone remodelling in this same group of horses., Study Design: Randomised controlled experimental study., Methods: Seven exercised Thoroughbred horses received a single im administration of 1.8 mg/kg clodronate and four horses received an equivalent volume of saline. Blood and urine samples were collected prior to, during and for 182 days post drug administration for drug concentration determination using liquid chromatography-tandem mass spectrometry, and determination of protein biomarker (CTX-1 and TRAcP5B) concentrations., Results: Clodronate was detectable in blood for 14-175 days and for up to 175 days in urine. For some horses, concentrations were nondetectable at one time point but detectable at a subsequent time point. The terminal serum half-life ranged from 1.80 to 283.9 days. CTX-1 concentrations were significantly higher, relative to baseline, in both treated and control groups while concentrations of TRAcP5B were significantly lower in the treated group., Main Limitations: Relatively small number of horses studied., Conclusions: Based on assessment of protein biomarkers, clodronate appears to influence osteoclasts at label doses. Furthermore, results of this study support racing regulations that preclude horses administered bisphosphonates for medical reasons, from racing for a prolonged period of time., (© 2022 EVJ Ltd.)
- Published
- 2023
- Full Text
- View/download PDF